Analysed BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
18-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
22-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
28-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
29-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
02-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
08-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
09-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading
10-06-2026
yahoo.com
What is the current price of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The current price of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is $3.04.
BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) since the previous trading day is $-0.0422.
BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) since the previous trading day is -1.3692%.
What is the most recent average sentiment score for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The most recent average sentiment score for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is 38 out of 100.
What is the most recent average sentiment for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)?
The most recent sentiment for BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ) is .
SEC-8K** Filing Available For BIODEXA PHARMACEUTICALS-ADR (BDRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.